Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Business Strategies Commercial

Taking Action On Diversity, BIO Challenges CEOs To Pursue Business Benefits

  • Interviews

Executive Summary

Scrip spoke with Halozyme CEO Helen Torley, chair of BIO's Workforce Development, Diversity and Inclusion committee, about efforts to communicate the benefits of diverse leadership to CEOs and build a database of diverse board candidates.

You may also be interested in...



Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis

Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem. 

Leading A Diverse Company: Biopharma Executives Offer Ways Forward

BIO hosted discussions during its annual meeting to reinforce the value of inclusion, offer advice to companies and reflect on recent US events. 

Leading A Diverse Company: Biopharma Executives Offer Ways Forward

BIO hosted discussions during its annual meeting to reinforce the value of inclusion, offer advice to companies and reflect on recent US events.

Table

View full table

Topics

Related Companies

Tags:
Leadership Business Strategies Commercial
Latest Headlines

Paradox Of China Biotech And What Lies Ahead In 2023

'Pivotal Time For CROs': ICON CEO Cutler On Changing APAC Trial Trends

Quick Listen: Scrip's Five Must-Know Things

Deal Watch: Sol-Gel To Tackle Gorlin Syndrome In Pact With BridgeBio’s PellePharm

See All
UsernamePublicRestriction

Register

SC123182

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By